Shares of Amprius Technologies (NYSE: AMPX) rallied approximately 10% in Monday's premarket session after the battery manufacturer announced a grant worth up to $75 million from the U.S. Department of War. Shares changed hands around $10.70 following the announcement — meaningful appreciation for the company as it continues to expand its defense-sector presence.

The funding originates from the Department of War's Industrial Base Analysis and Sustainment (IBAS) program, an initiative that supports onshore manufacturing capabilities deemed critical for national security interests, according to an official announcement published via Business Wire () and covered by Blockonomi (https://blockonomi.com/amprius-ampx-stock-surges-10-following-75m-pentagon-defense-contract/).
Amprius confirmed the award in a post on X:

"Amprius is honored to have been awarded a grant of up to $75 million from the United States @DeptofWar through the Industrial Base Analysis and Sustainment (IBAS) program. Read more below: $AMPX #IBAS #defensetech pic.twitter.com/rS5ZDXymat"

— Amprius Technologies (@AmpriusInc) September 28, 2026 (https://x.com/AmpriusInc/status/2104503955971813630?ref_src=twsrc%5Etfw)

PRODUCTION FACILITY DETAILS

The grant will enable Amprius to transform an existing domestic electric vehicle battery production line currently operated by a prominent South Korean manufacturer. The reconfigured plant will produce high-energy density battery cells designed for unmanned aerial systems, serving Group 1, 2 and 3 drones — a category encompassing small through medium-sized unmanned aircraft platforms.

The facility aims for operational readiness by early 2028. At full capacity, annual production will reach approximately 12 million Amprius cells. Total investment for the transformation project amounts to roughly $100 million, with Amprius and its South Korean manufacturing partner providing in-kind contributions to bridge the funding difference beyond the grant allocation.

Cells produced at the site will satisfy National Defense Authorization Act (NDAA) sourcing requirements. NDAA compliance creates access to defense procurement opportunities unavailable to foreign-manufactured batteries.

Amprius CEO Tom Stepien described the grant as establishing "a primary source of domestic, NDAA-compliant battery production." He highlighted the combination of Amprius technology with South Korean manufacturing expertise as a competitive advantage.

COMPANY TECHNOLOGY AND OPERATIONS

Amprius specializes in silicon anode lithium-ion batteries engineered for superior energy density. The core value proposition centers on delivering greater power capacity with reduced weight — a technology profile aligned with aviation applications, electric vehicles and light electric vehicles. The customer base includes drone operators and high-altitude pseudo-satellite platforms, where weight optimization is critical.

In unmanned aviation, weight saved on cells can translate directly into payload or endurance — the trade-off that makes energy density a decisive design parameter for the small and medium drone classes this plant will supply.

The company's silicon anodes serve as drop-in replacements for the conventional graphite anodes found in standard lithium-ion batteries, and its manufacturing processes integrate with established battery supply chains, minimizing infrastructure requirements. The recent grant expands a manufacturing network already present across China, South Korea and the United States, with the domestic production capability receiving substantial enhancement.

RECENT FINANCIAL PERFORMANCE

Financially, Amprius reported a second-quarter adjusted loss of 2 cents per share in August, with results aligned with analyst projections. Quarterly revenue reached $34.03 million, exceeding the $29.30 million consensus estimate.

For fiscal 2026, company guidance projects revenue exceeding $140 million, compared with the Street estimate of $132.10 million. Management anticipates a GAAP loss of 8 cents per share for the full year, slightly above the 7-cent loss analysts forecasted.

ANALYST COVERAGE

Wall Street sentiment remains constructive on the overall outlook. Amprius holds a Buy consensus rating among analysts with a mean price objective of $31.50. Jones Trading launched coverage in July with a Buy rating and a $30 price target. Clear Street initiated coverage in June, also assigning a Buy rating with a $33 target. Needham has maintained its Buy rating and $20 price target since March.

CONTRACT STRUCTURE

The grant operates under an Other Transaction Agreement designated as Project acCELLerate. This fixed-price, milestone-driven agreement includes approximately $22 million already committed from FY2025 appropriations, spanning September 2026 through September 2028.

With the agreement running through September 2028, milestone completions under the fixed-price structure — together with progress toward the early 2028 operational start and the roughly 12 million cells-per-year capacity target — are the concrete checkpoints to watch as the project moves from announcement to execution.